A phase II trial of PCNU in patients with malignant melanoma and central nervous system metastases

L. D. Feldman; L. G. Feun; R. S. Benjamin; B. S. Yap; C. Plager; N. Papadopoulos; N. Savaraj; M. A. Burgess; G. P. Bodey

doi:10.1097/00000421-198506000-00004

A phase II trial of PCNU in patients with malignant melanoma and central nervous system metastases

L. D. Feldman, L. G. Feun, R. S. Benjamin, B. S. Yap, C. Plager, N. Papadopoulos, N. Savaraj, M. A. Burgess, G. P. Bodey

Sarcoma Medical Oncology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Twelve patients with malignant melanoma metastatic to the central nervous system (CNS) were treated with PCNU. All patients had prior chemotherapy and/or radiation therapy and had progressive brain metastases, documented by computerized tomography. PCNU was given as a single intravenous infusion of 90-110 mg/m² every 6-8 weeks. There was one partial response and four patients had stable disease. Although no episodes of sepsis or bleeding occurred, seven of 17 courses led to significant granulocytopenia or thrombocytopenia. Non-hematopoietic toxicities were mild. These results indicate that systemic PCNU is unlikely to be more effective than other currently used chemotherapy in patients with malignant melanoma and CNS metastases.

Original language	English (US)
Pages (from-to)	215-217
Number of pages	3
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	8
Issue number	3
DOIs	https://doi.org/10.1097/00000421-198506000-00004
State	Published - 1985

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1097/00000421-198506000-00004

Cite this

@article{6d679b125db04e9987572a6adba6aedd,

title = "A phase II trial of PCNU in patients with malignant melanoma and central nervous system metastases",

abstract = "Twelve patients with malignant melanoma metastatic to the central nervous system (CNS) were treated with PCNU. All patients had prior chemotherapy and/or radiation therapy and had progressive brain metastases, documented by computerized tomography. PCNU was given as a single intravenous infusion of 90-110 mg/m2 every 6-8 weeks. There was one partial response and four patients had stable disease. Although no episodes of sepsis or bleeding occurred, seven of 17 courses led to significant granulocytopenia or thrombocytopenia. Non-hematopoietic toxicities were mild. These results indicate that systemic PCNU is unlikely to be more effective than other currently used chemotherapy in patients with malignant melanoma and CNS metastases.",

author = "Feldman, {L. D.} and Feun, {L. G.} and Benjamin, {R. S.} and Yap, {B. S.} and C. Plager and N. Papadopoulos and N. Savaraj and Burgess, {M. A.} and Bodey, {G. P.}",

year = "1985",

doi = "10.1097/00000421-198506000-00004",

language = "English (US)",

volume = "8",

pages = "215--217",

journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - A phase II trial of PCNU in patients with malignant melanoma and central nervous system metastases

AU - Feldman, L. D.

AU - Feun, L. G.

AU - Benjamin, R. S.

AU - Yap, B. S.

AU - Plager, C.

AU - Papadopoulos, N.

AU - Savaraj, N.

AU - Burgess, M. A.

AU - Bodey, G. P.

PY - 1985

Y1 - 1985

N2 - Twelve patients with malignant melanoma metastatic to the central nervous system (CNS) were treated with PCNU. All patients had prior chemotherapy and/or radiation therapy and had progressive brain metastases, documented by computerized tomography. PCNU was given as a single intravenous infusion of 90-110 mg/m2 every 6-8 weeks. There was one partial response and four patients had stable disease. Although no episodes of sepsis or bleeding occurred, seven of 17 courses led to significant granulocytopenia or thrombocytopenia. Non-hematopoietic toxicities were mild. These results indicate that systemic PCNU is unlikely to be more effective than other currently used chemotherapy in patients with malignant melanoma and CNS metastases.

AB - Twelve patients with malignant melanoma metastatic to the central nervous system (CNS) were treated with PCNU. All patients had prior chemotherapy and/or radiation therapy and had progressive brain metastases, documented by computerized tomography. PCNU was given as a single intravenous infusion of 90-110 mg/m2 every 6-8 weeks. There was one partial response and four patients had stable disease. Although no episodes of sepsis or bleeding occurred, seven of 17 courses led to significant granulocytopenia or thrombocytopenia. Non-hematopoietic toxicities were mild. These results indicate that systemic PCNU is unlikely to be more effective than other currently used chemotherapy in patients with malignant melanoma and CNS metastases.

UR - http://www.scopus.com/inward/record.url?scp=0022203515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022203515&partnerID=8YFLogxK

U2 - 10.1097/00000421-198506000-00004

DO - 10.1097/00000421-198506000-00004

M3 - Article

C2 - 4050740

AN - SCOPUS:0022203515

SN - 0277-3732

VL - 8

SP - 215

EP - 217

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

IS - 3

ER -

A phase II trial of PCNU in patients with malignant melanoma and central nervous system metastases

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this